BioCentury | Jan 5, 2009
Finance

Restructuring watch

...its annual cash burn to $5-$10M and have enough cash for operations into 2012 11/21/08 Curalogic...
BioCentury | Dec 22, 2008
Company News

Curalogic inflammation, autoimmune news

...its programs including Phase III vaccines for grass and ragweed allergies (see BioCentury, Dec. 8). Curalogic A/S...
BioCentury | Dec 15, 2008
Finance

Ebb & Flow

...NYSE:ELN) announced a restructuring that was rumored to be spurred in part by shareholder complaints; Curalogic...
...told Trinity Biotech (NASDAQ:TRIB) they would not be deterred from their planned board coup d'etat. Curalogic(al...
...year thinking about its strategic options after deciding to halt all its oral immunotherapy programs, Curalogic...
BioCentury | Dec 8, 2008
Company News

Curalogic inflammation, autoimmune news

...shareholders after it was unable to secure a partner for external development projects. In January, Curalogic...
...cash and a nine-month operating loss of DKK7.3 million ($1.4 million) (see BioCentury, Jan. 28). Curalogic A/S...
BioCentury | May 19, 2008
Company News

Curalogic inflammation news

...Responding to reports in the Danish media, Curalogic said it is no longer in discussions with...
...different potential transactions.” In January, the company restructured and reduced headcount (see BioCentury, Jan 28). Curalogic A/S...
BioCentury | Apr 7, 2008
Finance

1Q approvals/1Q setbacks

...one of two U.S. Phase III trials to treat post-operative pain following abdominal gynecological surgery Curalogic...
BioCentury | Apr 7, 2008
Finance

Restructuring watch

...disosorbide dinitrate will remain on the market to treat heart failure in black patients 1/21/08 Curalogic...
BioCentury | Jan 28, 2008
Clinical News

Grass allergy vaccine: Development discontinued

...of achieving positive results with the grass and house dust mite products is significantly reduced." Curalogic...
...completion with data expected in 3Q08. The cat allergy vaccine had completed Phase II testing. Curalogic A/S...
BioCentury | Jan 28, 2008
Clinical News

Ragweed allergy vaccine: Development discontinued

...of achieving positive results with the grass and house dust mite products is significantly reduced." Curalogic...
...completion with data expected in 3Q08. The cat allergy vaccine had completed Phase II testing. Curalogic A/S...
BioCentury | Jan 28, 2008
Finance

Ebb & Flow

...patients with inadequate responses to anti-TNF biologics. Roche markets it elsewhere as MabThera (see B13). Curalogic...
Items per page:
1 - 10 of 51
BioCentury | Jan 5, 2009
Finance

Restructuring watch

...its annual cash burn to $5-$10M and have enough cash for operations into 2012 11/21/08 Curalogic...
BioCentury | Dec 22, 2008
Company News

Curalogic inflammation, autoimmune news

...its programs including Phase III vaccines for grass and ragweed allergies (see BioCentury, Dec. 8). Curalogic A/S...
BioCentury | Dec 15, 2008
Finance

Ebb & Flow

...NYSE:ELN) announced a restructuring that was rumored to be spurred in part by shareholder complaints; Curalogic...
...told Trinity Biotech (NASDAQ:TRIB) they would not be deterred from their planned board coup d'etat. Curalogic(al...
...year thinking about its strategic options after deciding to halt all its oral immunotherapy programs, Curalogic...
BioCentury | Dec 8, 2008
Company News

Curalogic inflammation, autoimmune news

...shareholders after it was unable to secure a partner for external development projects. In January, Curalogic...
...cash and a nine-month operating loss of DKK7.3 million ($1.4 million) (see BioCentury, Jan. 28). Curalogic A/S...
BioCentury | May 19, 2008
Company News

Curalogic inflammation news

...Responding to reports in the Danish media, Curalogic said it is no longer in discussions with...
...different potential transactions.” In January, the company restructured and reduced headcount (see BioCentury, Jan 28). Curalogic A/S...
BioCentury | Apr 7, 2008
Finance

1Q approvals/1Q setbacks

...one of two U.S. Phase III trials to treat post-operative pain following abdominal gynecological surgery Curalogic...
BioCentury | Apr 7, 2008
Finance

Restructuring watch

...disosorbide dinitrate will remain on the market to treat heart failure in black patients 1/21/08 Curalogic...
BioCentury | Jan 28, 2008
Clinical News

Grass allergy vaccine: Development discontinued

...of achieving positive results with the grass and house dust mite products is significantly reduced." Curalogic...
...completion with data expected in 3Q08. The cat allergy vaccine had completed Phase II testing. Curalogic A/S...
BioCentury | Jan 28, 2008
Clinical News

Ragweed allergy vaccine: Development discontinued

...of achieving positive results with the grass and house dust mite products is significantly reduced." Curalogic...
...completion with data expected in 3Q08. The cat allergy vaccine had completed Phase II testing. Curalogic A/S...
BioCentury | Jan 28, 2008
Finance

Ebb & Flow

...patients with inadequate responses to anti-TNF biologics. Roche markets it elsewhere as MabThera (see B13). Curalogic...
Items per page:
1 - 10 of 51